MedPath

Guy's And ST Thomas' NHS Foundation Trust

🇬🇧United Kingdom
Ownership
-
Established
1993-01-01
Employees
25
Market Cap
-
Website
https://www.guysandstthomas.nhs.uk/
pharmaphorum.com
·

Reaching for the gold standard of lung cancer screening

Early detection of lung cancer is crucial for better outcomes, yet stigma and lack of awareness hinder screening uptake. A partnership between AstraZeneca and the NHS launched the 'Check Your Lungs' campaign, using innovative marketing to increase awareness and screening rates. This collaboration highlights the importance of early diagnosis and the role of partnerships in improving cancer care.
mirror.co.uk
·

Dad dies after being told he had just weeks to live after years of cutting kitchen worktops

Marek Marzec, a father of three, died from silicosis caused by inhaling quartz dust while cutting kitchen worktops. He sought to raise awareness and legal action against unsafe working conditions. His death highlights the urgent need for safety improvements in the engineered stone industry to prevent further tragedies.
finance.yahoo.com
·

Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis

Interim data from a Phase 2 study of SNT-5505 in myelofibrosis patients shows safety, tolerability, and significant symptom and spleen volume improvements over 52 weeks. SNT-5505, combined with RUX, demonstrated durable benefits, with 80% of evaluable patients achieving symptom relief by Week 38 and spleen volume reductions in 82%. The study, involving 16 patients, highlights SNT-5505's potential for long-term benefits in MF treatment.
morningstar.com
·

Albus Health Device Detects Early Warning Signs of Child Asthma Attacks Up To Five Days

Albus Health's AI-powered device detects child asthma attacks up to 5 days before onset, potentially transforming respiratory care by enabling early intervention.
kcl.ac.uk
·

Secretaries of State for Health and Science unveil new cutting-edge scanner at King's

Wes Streeting MP and Peter Kyle MP unveiled a new total-body PET scanner at St Thomas’ Hospital, which is 5 times more sensitive and 2-4 times faster, aiding quicker diagnoses and detailed whole-body readings. Managed by King’s and Imperial College London, it feeds into the National PET Imaging Platform, improving disease understanding and medicine development. The scanner benefits patients like Sarah Corfield, who found it less claustrophobic and quicker. Both secretaries praised the scanner for its potential to save lives through earlier detection and faster diagnoses.
news-medical.net
·

New injection treatment could be a game-changer for people with asthma and COPD

Benralizumab injection during asthma and COPD attacks reduces need for further treatment by 30%, outperforming steroid tablets, according to a study in The Lancet Respiratory Medicine.
miragenews.com
·

Breakthrough Asthma Attack Treatment in 50 Years

A new injection for asthma and COPD attacks is 30% more effective than steroid tablets, reducing the need for further treatment. The study, published in The Lancet Respiratory Medicine, found benralizumab, a monoclonal antibody, to be more effective at the point of exacerbation compared to prednisolone. This could be a significant advancement in treating eosinophilic exacerbations, which make up a significant portion of asthma attacks and COPD flare-ups.
express.co.uk
·

"Miracle" drug sees blood cancer patients given second chance of life

Avapritinib, a new drug, has been approved by NICE for treating advanced systemic mastocytosis, offering significant improvements and even complete remission in some patients, drastically improving quality of life and survival rates.
quantisnow.com
·

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase ...

Infigratinib, an oral FGFR3 inhibitor, showed significant increases in annualized height velocity (AHV) in children with achondroplasia in PROPEL 2, with a mean change of +2.50 cm/year at Month 18. The treatment also improved body proportionality and was well-tolerated, with no serious adverse events. Infigratinib has received Breakthrough Therapy Designation from the FDA and is being evaluated in PROPEL 3, with enrollment expected to complete by end of 2024.
globenewswire.com
·

BridgeBio Pharma Announces Publication in the New England

Infigratinib, an oral FGFR3 inhibitor, showed significant increases in annualized height velocity (AHV) in children with achondroplasia in PROPEL 2, with a mean change of +2.50 cm/year at Month 18. The treatment also improved body proportionality and was well-tolerated, with no serious adverse events. Infigratinib has received Breakthrough Therapy Designation from the FDA and is being evaluated in PROPEL 3, with enrollment completion expected by end of 2024.
© Copyright 2025. All Rights Reserved by MedPath